id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-003926-ycdaw2vh	Maslow, Joel N.	Zika Vaccine Development—Current Progress and Challenges for the Future	2019-07-14		.txt	text/plain	3766	189	43	Of note, the first demonstration of immunoprotection was as part of a 1953 study to define the ultrastructural characteristics of Zika virus, that found intramuscular vaccination of mice with infectious viral filtrates protected against cerebral infection [36] . In pre-clinical studies, vaccinated mice and non-human primates were shown to develop B and T-cell immune responses against the Zika virus envelope and protected against development of neurologic disease and death in immunosuppressed, interferon α, β receptor deficient (IFNAR) mice [43] . A subsequent study in non-human primates vaccinated twice at four-week intervals with alum generated binding and microneutralization antibody titers of 3.54 and 3.55 log10, respectively, and complete protection against viremia and viruria following challenge with either Brazilian or Puerto Rican strains of Zika virus [47] . Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study	./cache/cord-003926-ycdaw2vh.txt	./txt/cord-003926-ycdaw2vh.txt